T he immunomodulators R-848 (S-28463) and R-837 (imiquimod) and the inactive analogue S-26424 belong to the imidazoquinoline class of compounds. These compounds have been previously shown to have potent antiviral and antitumor properties in animals, and imiquimod has recently been indicated for treatment of genital warts caused by papilloma virus infection in humans (1) (2) (3) (4) (5) (6) . In addition to their previously demonstrated effectiveness in inducing cytokine secretion by monocytes and dendritic cells, the imidazoquinolines have been recently shown to possess potent activating properties for B lymphocytes (7) (8) (9) (10) (11) . We have found that the properties of R-848 show remarkable similarity to physiologic effector functions induced in the B cell via its membrane CD40 molecules. In both normal B cells (11) . However, each of these receptors uses distinct initial signaling pathways. Thus, although R-848 shows marked similarity to CD40 signaling in its effects on the B cell, the signaling pathways used to achieve these results may differ.
Understanding the mechanism of action of low molecular weight organic compounds such as R-848 in B lymphocyte activation is of considerable interest, as they are structurally quite different from the receptors whose signaling effects they mimic. Experiments in progress have revealed that R-848 does not exert its effects by engaging a cell surface receptor on B cells, but it is not yet clear to which intracellular structures or receptors it binds (M. A. Tomai, unpublished observations). We thus undertook this study to determine which signaling pathways are exploited by the drug to result in B cell activation. Information such as this can contribute to both increased understanding of B cell activation pathways as well as improved small molecule design for enhanced activation of immune responses.
Materials and Methods

Cells
The mouse B cell lines CH12.LX and CHB3 have been previously described (15, 16) . Production and characterization of CH12.LX cells expressing the Lac repressor (CH12.LAC) (17) as well as those inducibly expressing a mutant form of IB␣ (18) or truncated, dominant negative, mutant TNFR-associated factor 2 (TRAF2) 3 and TRAF3 (19) were described previously. The human EBV Ϫ B cell line Ramos was obtained from American Type Culture Collection (Manassas, VA). Cell lines were grown in RPMI 1640 containing 10% heat-inactivated FCS, 10 Ϫ5 M 2-ME, and antibiotics (B cell medium (BCM)). Resting splenic B cells from normal 7-to 10-wk-old female (B6 ϫ 129/J)F 2 hybrid mice or p50 Ϫ/Ϫ knockout mice (provided by Arthur Krieg, University of Iowa, Iowa City, IA) were purified on a discontinuous Percoll density gradient as previously described (20) . Small dense B cells were recovered from the 70 to 75% interface for use in experiments.
Drugs and reagents
The structures of R-848 (S-28463, 4-amino-2-ethoxymethyl-␣,␣-dimethyl-1H-imidazo- [4,5-c] quinoline-1-ethanol) and its inactive analogue S-26424 have been previously described (1) . These compounds are proprietary molecules of 3M Pharmaceuticals (St. Paul, MN) and are used as HCl salts. The drugs were dissolved in BCM and stored as stock solutions at 4°C for up to 1 mo. Recombinant mouse IL-6 was purchased from PharMingen (San Diego, CA), and recombinant mouse TNF-␣ was purchased from Endogen (Woburn, MA). Isopropylthio-␤-D-galactoside (IPTG) was purchased from Life Technologies (Gaithersburg, MD).
Antibodies
The 1C10 anti-mouse CD40 hybridoma was a gift from Dr. Frances Lund (Trudeau Institute, Saranac Lake, NY). The EM95 hybridoma, which served as an isotype control for 1C10 stimulation, was provided by Dr. Thomas Waldschmidt (University of Iowa). The G28-5 hybridoma producing anti-human CD40 mAb and hybridomas producing the anti-mouse IL-6 mAbs 20F311 and 32C11 were obtained from American Type Culture Collection. The above-mentioned mAbs were purified from hybridoma supernatants using saturated ammonium sulfate precipitation. The anti-TNF-␣ mAbs MP6-XT22 and MP6-XT3 were gifts from Dr. John Harty (University of Iowa). Abs specific for NF-B p50, p52, p65 (Rel-A), c-Rel, and Rel-B were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-rabbit IgG-HRP was purchased from Bio-Rad (Hercules, CA).
c-Jun kinase assay
CH12.LX cells or resting splenic B cells (5 ϫ 10 6 or 10 7 /condition, respectively) were incubated with 1 g/ml of R-848, its inactive analogue, the anti-CD40 mAb 1C10, or its isotype control EM95 for 5 min (CH12.LX) or 10 min (splenic B cells) at 37°C. Cells were then lysed, and c-Jun kinase activity was measured as described previously (18) . Reactions were separated by SDS-PAGE. Gels were stained with Coomassie blue and dried. Phosphorylated c-Jun was visualized by autoradiography.
Assay for p38 kinase
CH12.LX cells or resting splenic B cells were stimulated with R-848 or its inactive analogue for 5 min (CH12.LX) or 10 min (splenic B cells) at 37°C. Cells were centrifuged at 500 ϫ g for 5 min at 4°C and washed once with ice-cold PBS. Cells were lysed, and p38 kinase activity was assayed using a p38 mitogen-activated protein kinase kit (New England Biolabs, Beverly, MA), according to the manufacturer's protocol. An in vitro kinase assay was performed in supplied kinase buffer containing 20 M ATP, 0.5 Ci [␥-32 P]ATP, and GST-activating transcription factor 2 as a substrate for 30 min at room temperature. The reaction was terminated with an equal volume of 2ϫ SDS buffer, and samples were heated at 95°C for 5 min. Samples were resolved by 12% PAGE, and the phosphorylated activating transcription factor 2 substrate band was visualized using autoradiography.
Nuclear extraction and EMSA
CH12.LX, CHB3, Ramos, or splenic B cells (10 7 /sample) were stimulated at a concentration of 10 6 /ml with 1 g/ml of R-848 or its inactive analogue S-26424 for 5 min to 2 h at 37°C. Nuclear extracts were then prepared from cells as previously described (21) . Extracts were recovered, quantitated against a BSA protein standard, and stored at Ϫ70°C in the presence of 5 g/ml antipain, 30 g/ml leupeptin, 50 g/ml aprotinin, and 400 M sodium vanadate. Double-stranded DNA probes were end labeled with [␥-32 P]ATP using T4 polynucleotide kinase. The sequence of the probe for NF-B was described previously (21) . A total of 5 g of nuclear extract was incubated with 0.5 ng of probe for 30 min. Samples were separated on a 5% native polyacrylamide gel at a constant current of 20 mA. X-ray film was exposed to dried gels overnight at Ϫ70°C.
Ab secretion assays
To induce Ab secretion, CH12.LX cells (1500 cells/well in 150 l) inducibly expressing IB␣AA or dominant negative TRAF2 (DNTRAF2) or DNTRAF3 were incubated for 24 h in 96-well flat-bottom microtitration plates in the presence of 100 M IPTG to induce production of the IB␣AA or DNTRAF proteins. Various stimuli were then added in a volume of 50 l, and cells were incubated for an additional 48 h. Stimuli included various combinations of the following, all determined in preliminary experiments to be saturating final concentrations: R-848 (200 ng/ml), the anti-CD40 mAb 1C10 (1 g/ml), IL-6 (10 ng/ml), the anti-IL-6 mAbs 32C11 and 20F311 (3 g/ml), TNF-␣ (25 ng/ml), or the anti-TNF mAbs MP6-XT22 and MP6-XT3 (5 g/ml). CH12.LX cells inducibly produce IgM specific for an Ag, phosphatidylcholine, which is present on the membranes of SRBC (22) . Differentiation to Ig-secreting cells can thus be quantitated by counting the number of cells in each replicate culture capable of forming lytic plaques on a lawn of SRBC at the end of the culture period as previously described (23) . Results are presented as the mean number of plaque-forming cells per viable cells recovered from replicate cultures.
Results
R-848 stimulates activation of c-Jun kinase and p38 in B cells
One of the earliest events induced by CD40 signaling in B cells is the activation of the stress-activated protein kinases c-Jun kinase and p38 (24 -26) . R-848 also rapidly induced both kinases in the representative B cell line CH12.LX, as well as in purified splenic B cells (Fig. 1) . Similar results were found by cross-linking either mouse or transfected human CD40. The inactive analogue of R-848 (S-26424), however, had no effect on the activity of these kinases in either cell type.
R-848 induces NF-B activation in both mouse and human B cells
CD40 signaling to B cells induces strong activation of the NF-B family of transcription factors, and this event has been shown to be necessary for CD40-mediated B cell differentiation and up-regulation of the B7 costimulatory molecules (18) . As it has been recently shown that R-848, like CD40, induces B cell differentiation to Ab secretion and can enhance CD40-mediated B7 up-regulation (11), it was of interest to determine whether R-848 also induces NF-B activation in B cells. shows that R-848 induced levels of NF-B translocation similar to those stimulated via CD40, and the use of cold competitor probes demonstrated that the activation was specific.
This effect was not confined to cell lines; the drug also induced NF-B activation in normal resting mouse splenic B cells (Fig. 3) , similar to the induction seen using agonistic anti-CD40 mAbs. Of particular interest was the finding that although a CD40 signal no longer induced NF-B nuclear translocation in mice genetically deficient in the NF-B p50 subunit, R-848 still induced NF-B activation in the B cells of p50 Ϫ/Ϫ mice. We have previously shown that CD40-mediated NF-B activation in B cells involves nuclear translocation of the family members p50, p65, and c-Rel (21) . The data shown in Fig. 3 raise the possibility that R-848 activates the translocation of different NF-B subunits. In Fig. 3 , the shifted complex differs in size from that seen in wild-type mice; however, this was not a consistent finding. To determine whether different NF-B subunits are involved in CD40 vs R-848-mediated NF-B activation, supershift analysis was performed. 
R-848-mediated Ab secretion is dependent upon NF-B activation
Previous studies showed that CD40-mediated differentiation of B cells to Ab secretion is highly dependent upon CD40-induced NF-B activation (18) . We have found that R-848, like CD40, induces Ab secretion and synergizes with signals delivered through the B cell Ag receptor. It was thus of interest to determine whether the R-848-mediated activation of NF-B is required for the ability of the drug to induce Ab production. To do so, we used a subclone of CH12.LX that stably and inducibly expresses a mutant form of the NF-B inhibitory molecule, IB␣. In this mutant molecule (IB␣AA), the two serine residues that are phosphorylated as a consequence of activation signals, leading ultimately to the degradation of IB␣, have been changed to alanines. Expression of the mutant protein is normally repressed by constitutive expression of the bacterial Lac operon repressor protein (LacR) in this cell line, but can be induced by inclusion of IPTG in the culture medium. We have previously shown that induced expression of IB␣AA in CH12.LX effectively blocks NF-B activation (18) . Fig. 5A shows that R-848-mediated activation of B cells expressing only LacR (CH12.LAC) was not inhibited by IPTG, but cells induced to express IB␣AA showed highly diminished Ab secretion in response to the drug. This dependence of the Ab response on NF-B activation was quite similar to that seen for CD40 signaling, as shown in Fig. 5B , where the two stimuli are compared in the same experiment. Thus, NF-B activation by R-848 is important for mediating the downstream effects of the drug on B lymphocytes.
R-848-induced differentiation involves both IL-6 and TNF
We have recently found that R-848 treatment of B cells increases both the gene expression and protein production of the cytokines IL-6 and TNF (G. A. Bishop and M. A. Tomai, manuscript in preparation), both of which have been shown to stimulate B cell Ab Ϫ/Ϫ mice. Small, dense, resting splenic B cells were purified as described in Materials and Methods and stimulated for 20 min with BCM alone (lane 2), 1 g/ml analogue plus 1 g/ml isotype control mAb EM95 (lanes 3 and 6), 1 g/ml 1C10 (lanes 4 and 7) , or 1 g/ml R-848 (lanes 5 and 8). Lane 1 contained labeled probe alone, which migrated to the bottom of the gel and is thus not visible here. EMSA was performed as described in Materials and Methods. Results are representative of two similar experiments. Wt, wild type. production (27) . To extend these findings, we wished to determine whether either cytokine was involved in R-848-mediated B cell differentiation. Fig. 6A shows that treatment of CH12.LX cells with a saturating amount of exogenous IL-6 (the maximal amount induced by R-848) induced Ab production, although not to the same extent as R-848 itself. R-848-induced differentiation could be completely blocked with a saturating concentration of the IL-6-blocking mAb, 20F3-11 (second set of bars), but was unaffected by a nonblocking IL-6-specific mAb (32C11). Fig. 6A also shows that R-848-induced Ab production was inhibited ϳ50% by treatment with 20F3-11. This suggests that IL-6 is an important component of the mechanism by which R-848 induces B cells to secrete Ab, but cannot completely account for the effect. Fig. 6B shows that, similarly, a saturating amount of exogenously added TNF-␣ stimulated Ab secretion by CH12.LX, but was less effective than R-848 itself. A mixture of two anti-TNF-blocking mAbs also reduced R-848-induced Ab secretion, by ϳ60%. Finally, the results shown in Fig. 6C demonstrate that the presence of blocking Abs to both IL-6 and TNF reduced CD40-and R-848-stimulated Ab production to a greater extent than blocking either cytokine alone. These results indicate that both IL-6 and TNF play important roles in R-848-induced B cell differentiation.
TRAF2 molecules play a role in R-848-mediated signaling
CD40 is a member of the TNF receptor (TNF-R) family of molecules, and the cytoplasmic proteins known as TRAFs have been strongly implicated as playing important roles in signaling through this family of molecules (28) . The TRAFs are thought to exert their effects by direct binding to the cytoplasmic domains of the various TNF-R family molecules in whose functions they are involved. However, we have recently shown that TRAF2 can strongly influence CD40-mediated B cell differentiation even when it cannot directly associate with CD40 (19) . An indirect way in which TRAF2 could influence Ab secretion is that CD40 signals are known to induce B cell TNF-␣ production, and TNF can induce Ab secretion (27, 29) . In addition, we have recently found that R-848 induces CH12.LX cells to produce TNF-␣ (G. A. Bishop and M. A. Tomai, manuscript in preparation). TRAF2 binds to the cytoplasmic domains of both CD40 and the TNF-R (28), so it could indirectly influence CD40-and/or R-848-induced Ab secretion by affecting TNF-R signaling. We thus tested whether induced expression of a truncated, DNTRAF2 molecule in B cells affects R-848-induced differentiation, as Fig. 6B shows that this effect is partially dependent upon TNF production. Fig. 7A shows that induced expression of DNTRAF2 inhibits both CD40-and R-848-mediated Ab secretion to approximately the same extent as does treatment with anti-TNF mAbs (see Fig. 6B ). We have recently found that DNTRAF2 also inhibits TNF-induced Ab production by CH12.LX cells (G. A. Bishop and B. S. Hostager, manuscript in preparation). However, induced expression of DNTRAF3, which binds CD40 but not the TNF-R, inhibits only CD40-mediated differentiation and does not affect R-848-mediated activation (Fig. 7B) .
Discussion
The present study was designed to investigate the molecular mechanisms of B lymphocyte activation by the immunomodulator R-848. The ability of this agent to stimulate B cell function has important implications for its potential as a vaccine adjuvant in stimulating B cell responses, particularly as it clearly mimics in many ways the signals received by B cells through their CD40 molecules. Indeed, imiquimod has been shown to act as a vaccine adjuvant when given together with herpes simplex virus glycoprotein D in guinea pigs (30, 31) . Understanding how R-848 mediates its effects can lead to development of even more effective immunomodulatory agents as well as allow optimization of its use.
Similar to the natural signal provided by CD40 ligation (18), R-848 stimulates activation of stress-activated protein kinases (Fig. 1) . There is no evidence, however, that R-848 directly activates protein tyrosine kinases (M. A. Tomai, unpublished observations). Similarly, although there is indirect evidence that CD40 signaling may ultimately involve tyrosine kinases, convincing in vivo evidence that CD40 associates with tyrosine kinases has been difficult to obtain (reviewed in Ref. 32 ). R-848, like CD40 (21) and another potential new adjuvant, CpG oligonucleotides (33) also activates the NF-B family of transcription factors (Figs. 2 and 3) , and R-848-induced IgM secretion depends upon NF-B activation (Fig. 4) . NF-B activation by the imidazoquinolines has also been demonstrated in human monocytes (10) . The activation of members of the NF-B family has been shown to make important contributions to many immune activation processes (34) and provides an important proviability signal to cells (35) (36) (37) (38) (39) . Of particular interest was the finding that although CD40-induced NF-B activation was dependent upon the p50 subunit, R-848-induced NF-B activation, although inducing nuclear translocation of p50, was able to proceed in the absence of this subunit (Fig. 3) . This result suggests that although the two types of signal are each able to induce nuclear translocation of the same Rel family subunits, CD40 preferentially stimulates the movement of hetero-and homodimers containing p50, while R-848 can also stimulate translocation of dimers lacking p50.
Our previous studies showed that R-848 induces production of a variety of cytokines in cells of the immune system, including B lymphocytes (7, 40) . The present study determined that R-848-induced B cell production of both TNF-␣ and IL-6 play important roles in R-848-induced Ab secretion (Fig. 6 ). IL-6 has been shown to potently preserve B cell viability (27, 41, 42) and stimulate B cell differentiation (27, (43) (44) (45) (46) . Additionally, IL-6 production has been demonstrated to play a significant role in CD40-mediated B cell differentiation (47) (48) (49) . Thus, R-848 again shows its ability to mimic signals delivered to B cells during normal T-dependent Ab responses. Although TNF can induce apoptosis in a variety of cells via the type I TNF-R (50), it has been shown that TNF induces human B cells to secrete Ab (27, 51) , a finding we have recently reproduced in mouse B cells (B. S. Hostager and G. A. Bishop, manuscript in preparation). Thus, TNF production induced by R-848 has a positive effect in stimulating an Ab response. We also show that this effect requires participation of the cytoplasmic adapter molecule TRAF2, which has been shown to participate in signal transduction via the TNF-R (52). The result that DNTRAF3, which binds CD40 but not the TNF-R, does not affect R-848 signaling (Fig. 7) supports the hypothesis that TRAF2 affects R-848 signaling indirectly via affects on TNF-R signaling.
IL-6 and TNF are known mediators of inflammation in a variety of clinical situations (53, 54) , and a number of therapeutic strategies have sought to block the actions of these cytokines. However, in designing more effective vaccines and adjuvants, it may clearly prove desirable to stimulate B lymphocyte production of IL-6 and TNF to obtain a more effective initial Ab response. The present study shows that R-848 can achieve this response, using molecular mechanisms remarkably similar to those used by CD40 signaling to B lymphocytes. The ability of R-848 to stimulate IL-12 production may also contribute to the potential of this compound as an adjuvant (7, 9) . Mimicking the normal T cell-dependent pathways of B cell activation may prove a promising strategy to effective manipulation of the adaptive Ab response. 
